Oral Pre-Exposure Prophylaxis for HIV Discontinuation in a Large Cohort of Adolescent Men Who Have Sex With Men and Transgender Women in Brazil

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
ZEBALLOS, Diana
MAGNO, Laio
SOARES, Fabiane
EUSTORGIO FILHO, Marcos
AMORIM, Leila
PINTO JR., Jony Arrais
GRECO, Dirceu
DOURADO, Ines
Citação
JOURNAL OF ADOLESCENT HEALTH, v.73, n.6, suppl.S, p.S43-S49, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: This study aimed to describe pre-exposure prophylaxis (PrEP) for HIV discontinuation in adolescent men who have sex with men (aMSM) and adolescent transgender women (aTGW) and to identify factors associated with discontinuation. Methods: The PrEP1519 study included a cohort of aMSM and aTGW aged 15-19 years old, and itwas conducted in three large Brazilian capital cities. For this analysis, we included adolescents who initiated PrEP. PrEP discontinuationwas defined as no possession of PrEP pills for >90 days. Kaplan-Meier curves were used to analyze the probabilities of discontinuation, and survival distributions stratified bycovariates were compared using log-rank or Wilcoxon tests. Cox regression models were used to estimate the adjusted hazard ratio (aHR) with a 95% confidence interval (95% CI). Results: We included 908 adolescents, 829 (91.30%) aMSM and 79 (8.70%) aTGW, most of whom were 18-19 years (80.29%). The incidence rate of discontinuation was 75.6 per 100 person-years. The probability of discontinuation was 52.61% in the first year. The multivariate analysis demonstrated that the aTGW (aHR = 1.63; 95% CI: 1.02-1.64) and adolescents with a medium (aHR = 1.29; 95% CI: 1.02-1.64) or low (aHR = 1.65; 95% CI: 1.29-2.12) perceived risk of HIV infection had an increased risk of discontinuation, whereas the adolescents with a partner living with HIV had a lower risk of discontinuation (aHR = 0.57; 95% CI: 0.35-0.91). Discussion: Adolescents with a high risk for discontinuation may need additional support that emphasizes the value of PrEP as a tool for HIV prevention because PrEP discontinuation was associated with a disconnect between HIV risk perception and HIV prevention. (c) 2023 Society for Adolescent Health and Medicine.
Palavras-chave
PrEP, Discontinuation, Adolescents, HIV prevention
URI
https://observatorio.fm.usp.br/handle/OPI/58102
Referências
  1. Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
  2. Boletim Epidemiologico HIV/Aids, 2021, About us
  3. Casey BJ, 2015, ANNU REV PSYCHOL, V66, P295, DOI 10.1146/annurev-psych-010814-015156
  4. Cohen AO, 2016, PSYCHOL SCI, V27, P549, DOI 10.1177/0956797615627625
  5. Corneli A, 2014, JAIDS-J ACQ IMM DEF, V67, P555, DOI 10.1097/QAI.0000000000000362
  6. Dourado I, 2023, Cad Saude Publica, V39
  7. Dourado I, 2020, AIDS BEHAV, V24, P1994, DOI 10.1007/s10461-020-02927-w
  8. Gilbert HN, 2019, JAIDS-J ACQ IMM DEF, V82, P265, DOI 10.1097/QAI.0000000000002139
  9. Gill K, 2020, LANCET CHILD ADOLESC, V4, P875, DOI 10.1016/S2352-4642(20)30248-0
  10. Goedel WC, 2022, JAIDS-J ACQ IMM DEF, V91, P151, DOI 10.1097/QAI.0000000000003042
  11. Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
  12. Greenwald Zoe R, 2019, BMJ Open, V9, pe028768, DOI 10.1136/bmjopen-2018-028768
  13. Hojilla JC, 2018, AIDS BEHAV, V22, P1096, DOI 10.1007/s10461-017-2009-x
  14. Hosek SG, 2017, JAMA PEDIATR, V171, P1063, DOI 10.1001/jamapediatrics.2017.2007
  15. Irie W, 2022, CROI 2022 C RETR OPP, P374
  16. Jalil EM, 2022, J INT AIDS SOC, V25, DOI 10.1002/jia2.25896
  17. Krakower D, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25250
  18. Lall P, 2015, J INT AIDS SOC, V18, P41, DOI 10.7448/IAS.18.2.19393
  19. Magno L, 2022, Sex Educ, V23, P409
  20. Magno L, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311x00112718, 10.1590/0102-311X00112718]
  21. Nieto O, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241340
  22. Okoli C, 2021, SEX TRANSM INFECT, V97, P18, DOI 10.1136/sextrans-2020-054551
  23. Pettifor A, 2018, CURR OPIN HIV AIDS, V13, P265, DOI [10.1097/COH.0000000000000453, 10.1097/coh.0000000000000453]
  24. Pettifor A, 2015, J INT AIDS SOC, V18, P8, DOI 10.7448/IAS.18.2.19434
  25. Plotzker R, 2017, JAIDS-J ACQ IMM DEF, V76, P473, DOI 10.1097/qai.0000000000001536
  26. RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
  27. Rutstein SE, 2020, LANCET HIV, V7, pE721, DOI 10.1016/S2352-3018(20)30203-4
  28. Seekaew P, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25430
  29. Serota DP, 2020, CLIN INFECT DIS, V71, P574, DOI 10.1093/cid/ciz894
  30. Oliveira RLSE, 2023, CAD SAUDE PUBLICA, V39, DOI [10.1590/0102-311XEN176821, 10.1590/0102-311xen176821]
  31. Sperhacke RD, 2018, MEDICINE, V97, pS25, DOI [10.1097/MD.0000000000009014, 10.1097/md.0000000000009014]
  32. Spinelli MA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz101
  33. Steinberg L, 2018, DEVELOPMENTAL SCI, V21, DOI 10.1111/desc.12532
  34. Tao J, 2021, AIDS PATIENT CARE ST, V35, P271, DOI 10.1089/apc.2021.0074
  35. Therneau Terry M, 2000, Modeling Survival Data: Extending the Cox Model, DOI 10.1007/978-1-4757-3294-8_3
  36. UNAIDS DATA, 2021, About us
  37. Van Epps P, 2019, JAIDS-J ACQ IMM DEF, V82, P427, DOI 10.1097/QAI.0000000000002186
  38. Zhang J, 2022, LANCET HIV, V9, pE254, DOI 10.1016/S2352-3018(22)00030-3

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05